Keyphrases
Thrombus Formation
100%
Atorvastatin
100%
Hemostatic Profile
100%
Coronary Patients
62%
Coronary Artery Disease
50%
Non-coronary Artery Disease
50%
Low-density Lipoprotein Cholesterol (LDL-C)
37%
Placebo
25%
Lipid-lowering
25%
Perfusion Chamber
25%
Hemostatic Markers
25%
Lipid Profile
12%
Von Willebrand Factor
12%
Fibrinogen
12%
Early Effect
12%
Cholesterol
12%
Clinical Events
12%
C-reactive Protein
12%
Secondary Prevention
12%
Plasminogen Activator inhibitor-1 (PAI-1)
12%
D-dimer
12%
Primary Prevention
12%
Tissue Plasminogen Activator (t-PA)
12%
Stable Patients
12%
Thrombus
12%
6-month Follow-up
12%
Disease Groups
12%
Thrombotic
12%
Prothrombin Fragment
12%
Upper Normal Limit
12%
Factor VIIa
12%
Ex Vivo Perfusion
12%
Fibrinopeptide A
12%
Chamber System
12%
Dynamic Flow Conditions
12%
Pharmacology, Toxicology and Pharmaceutical Science
Hyperlipidemia
100%
Coronary Artery Disease
100%
Thrombus
100%
Pravastatin
100%
Hemostatic Agent
100%
Low Density Lipoprotein Cholesterol
27%
Placebo
18%
Fibrinolytic Agent
18%
Von Willebrand Factor
9%
Prothrombin
9%
Fibrinogen
9%
C Reactive Protein
9%
Dimer
9%
Plasminogen Activator Inhibitor 1
9%
Tissue Plasminogen Activator
9%
Fibrinopeptide A
9%